Innovation | Novartis United States of America

Novartis acquires Kedalion Therapeutics and its innovative ocular delivery platform that could transform patient experience

Reimagine MedicineInnovation
Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Reimagine MedicineInnovation
Novartis expands Beacon of Hope through alliances with Historically Black Medical Schools to address systemic health disparities

Reimagine MedicineInnovation
2004 Release

Reimagine MedicineInnovation
2005 Release

Reimagine MedicineInnovation
News Release 1 Headline

Reimagine MedicineInnovation
Photo: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment

Reimagine MedicineInnovation
Video and Photo: Tekturna HCT®, a Single-tablet Combination of Tekturna®* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure

Reimagine MedicineInnovation
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy

Reimagine MedicineInnovation
VIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy

Reimagine MedicineInnovation
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting

Reimagine MedicineInnovation
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer

Reimagine MedicineInnovation